HI Bio Reaches For The Lead With Phase II Primary Membranous Nephropathy Data

 
• By Joseph Haas
  
Autoantibody
HI-Bio takes an antiautobody-targeted approach to rare diseases • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D